Glenmark Pharmaceutical has announced the UK launch of Tiogiva, a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI), for the treatment of chronic obstructive pulmonary disease (COPD).

Tiotropium Bromide DPI is a bioequivalent version of Boehringer Ingelheim’s Spiriva Handihaler.

As per data from IQVIA, Tiotropium DPI’s market size was $450 million in the European Union in the 12-month period ended September 2020.

In August 2018, Glenmark Pharmaceutical’s subsidiary – Glenmark Pharmaceuticals Europe had entered into an exclusive in-licensing arrangement for marketing generic Tiotropium Bromide DPI in Western Europe and the UK.

The Indian pharma company said that it is planning the subsequent rollout of the COPD product across Western Europe under the brand name Tiogiva in Ireland, Sweden, Norway, and Finland, and Tavulus in Denmark, the Netherlands, and Spain, and Tiotropium Glenmark in Germany.

The generic Tiotropium Bromide DPI is the second inhalation product in-licensed by the company for the European market after Stalpex (Fluticasone/ Salmeterol) dry powder inhaler.

Achin Gupta – EVP and Business Head of EMEA-L, Glenmark Pharmaceuticals said: “We are glad to introduce Tiogiva, one of the first bioequivalent drugs to be launched in Europe for treatment of COPD.

“Respiratory medicine is a key area of focus for Glenmark and the launch of this product will enable us to improve access to COPD treatment by providing an effective and high quality treatment option to patients in UK and Western Europe.”

  Achin Gupta, Boehringer Ingelheim, chronic obstructive pulmonary disease, COPD, Glenmark Pharmaceuticals, Spiriva Handihaler, Tiogiva, Tiotropium Bromide, United Kingdom